1 active not recruiting, 1 completed, 1 not yet recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 1, Completed 1, Not yet recruiting 1 |
| Phase 2 | 3 | Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Recurrent Enteropathy-Associated T-Cell Lymphoma: new trials by email Literature Review of Recurrent Enteropathy-Associated T-Cell Lymphoma trials Research Report on Recurrent Enteropathy-Associated T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma Brentuximab Vedotin, Pembrolizumab - Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 2 | Withdrawn | Northwestern University | 2020-03-01 | 2023-10-10 | |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Terminated | Mayo Clinic | 12 | 2017-05-17 | 2020-04-21 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
Enteropathy-Associated T-Cell Lymphoma (5) · Lymphoma, T-Cell (5) · Immunoblastic Lymphadenopathy (4) · Lymphoma, Large-Cell, Anaplastic (4) · Mycosis Fungoides (3) · Subcutaneous panniculitis-like T-cell lymphoma (3) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · HTLV-I Infections (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Follicular (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1)
Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoma (5) · Lymphoma, Non-Hodgkin (5) · Lymphoproliferative Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Lymphadenopathy (4) · Lymphoma, T-Cell, Cutaneous (3) · Deltaretrovirus Infections (1) · Hematologic Diseases (1) · Hematologic Neoplasms (1) · Histiocytic Disorders, Malignant (1)
10-propargyl-10-deazaaminopterin (2) · pembrolizumab (2) · Azacitidine (1) · Brentuximab Vedotin (1) · Carboplatin (1) · Depsipeptides (1) · Etoposide (1) · Fluorodeoxyglucose F18 (1) · Ifosfamide (1) · Lactones (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Specimen Handling (1) · belinostat (1) · romidepsin (1)
City of Hope Medical Center (2) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · Northwestern University (1)
United States (5)
Alex F Herrera (1) · Christina Poh (1) · Jonathan Moreira, MD (1) · Michelle Fanale (1) · Stephen Ansell (1)
P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P30CA060553 (1)